Compare Marathon Digital Holdings Inc (MARA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Sanofi SA — how do they compare? Marathon Digital Holdings Inc trades at $9.63 (market cap $3.74B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 27.9× Marathon Digital Holdings Inc's market cap, and Sanofi SA pays a 5.55% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| MARA | SNY | |
|---|---|---|
Market Cap | $3.74B | $104.30B |
Sector | Technology | Health |
52-Week High | $22.84 | $52.34 |
52-Week Low | $6.73 | $41.33 |
Enterprise Value | $5.78B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA Holdings trades at $9.64, down 6% post-Q2 2026 results, with a bearish technical signal and negative earnings trends. The company reported a net loss of $1.31 billion in 2025, with revenue declining to $804 million in 2026. Recent news highlights a strategic pivot to AI infrastructure, but investor sentiment remains cautious amid Bitcoin mining sector weakness.
Outlook is mixed: analyst consensus targets $16.08 (67% upside), but high losses and sector volatility pose risks. The AI transition offers growth potential, yet execution challenges and persistent negative margins demand caution. Near-term pressure from missed earnings and competitive threats may limit upside.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
